Cargando…

Twincretin as a potential therapeutic for the management of type 2 diabetes with obesity

Unimolecular peptide‐based dual agonists against glucagon‐like peptide‐1 receptor (GLP‐1R) and glucose‐dependent insulinotropic polypeptide receptor (GIPR) have been gaining much attention recently as novel antidiabetic agents that can potentially control glycemia and bodyweight. Although GLP‐1 and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Usui, Ryota, Yabe, Daisuke, Seino, Yutaka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Commentaries
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6626965/ https://www.ncbi.nlm.nih.gov/pubmed/30637966 http://dx.doi.org/10.1111/jdi.13005

Ejemplares similares

Challenging Clinical Perspectives in Type 2 Diabetes with Tirzepatide, a First-in-Class Twincretin
por: MacIsaac, Richard J., et al.
Publicado: (2023)

Incretin concept revised: The origin of the insulinotropic function of glucagon‐like peptide‐1 – the gut, the islets or both?
por: Yabe, Daisuke, et al.
Publicado: (2017)

Dipeptidyl peptidase‐4 inhibitors and prevention of bone fractures: Effects beyond glyemic control
por: Yabe, Daisuke, et al.
Publicado: (2012)

Cardiovascular safety trials of incretin‐based drugs: What do they mean?
por: Yabe, Daisuke, et al.
Publicado: (2016)

Dipeptidyl peptidase‐4 inhibitors and sulfonylureas for type 2 diabetes: Friend or foe?
por: Yabe, Daisuke, et al.
Publicado: (2014)

Liraglutide in Adults with Type 2 Diabetes: Global Perspective on Safety, Efficacy and Patient Preference
por: Yabe, Daisuke, et al.
Publicado: (2011)

Relationship between deterioration of glycated hemoglobin‐lowering effects in dipeptidyl peptidase‐4 inhibitor monotherapy and dietary habits: Retrospective analysis of Japanese individuals with type 2 diabetes
por: Kuwata, Hitoshi, et al.
Publicado: (2017)

Incretin‐based drugs for type 2 diabetes: Focus on East Asian perspectives
por: Seino, Yutaka, et al.
Publicado: (2016)

β Cell Dysfunction Versus Insulin Resistance in the Pathogenesis of Type 2 Diabetes in East Asians
por: Yabe, Daisuke, et al.
Publicado: (2015)

Retrospective analysis of liraglutide and basal insulin combination therapy in Japanese type 2 diabetes patients: The association between remaining β‐cell function and the achievement of the glycated hemoglobin target 1 year after initiation
por: Usui, Ryota, et al.
Publicado: (2017)

Reply to the comment of Wilbrink et al. on Retrospective analysis of liraglutide and basal insulin combination therapy in Japanese type 2 diabetes: The association between remaining β‐cell function and the achievement of the HbA1c target 1 year after initiation
por: Usui, Ryota, et al.
Publicado: (2018)

Efficacy and safety of novel twincretin tirzepatide a dual GIP and GLP-1 receptor agonist in the management of type-2 diabetes: A Cochrane meta-analysis
por: Dutta, Deep, et al.
Publicado: (2021)

Impact of the angiotensin receptor‐neprilysin inhibitor in clinical diabetes management: Potential benefits and pitfalls
por: Kato, Tomoko, et al.
Publicado: (2023)

A Review of Recent Findings on Meal Sequence: An Attractive Dietary Approach to Prevention and Management of Type 2 Diabetes
por: Kubota, Sodai, et al.
Publicado: (2020)

Effects of glucagon‐like peptide‐1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study
por: Kuwata, Hitoshi, et al.
Publicado: (2021)

Δ9-Tetrahydrocannabivarin (THCV): a commentary on potential therapeutic benefit for the management of obesity and diabetes
por: Abioye, Amos, et al.
Publicado: (2020)

Retrospective analysis of safety and efficacy of insulin‐to‐liraglutide switch in Japanese type 2 diabetes: A caution against inappropriate use in patients with reduced β‐cell function
por: Usui, Ryota, et al.
Publicado: (2013)

The Asian Association for the Study of Diabetes: The first 10 years and the next 10 years
por: Seino, Yutaka, et al.
Publicado: (2020)

Efficacy and safety of once‐weekly semaglutide in Japanese individuals with type 2 diabetes by baseline age and body mass index
por: Yabe, Daisuke, et al.
Publicado: (2022)

Efficacy and safety of lixisenatide in Japanese patients with type 2 diabetes mellitus inadequately controlled by sulfonylurea with or without metformin: Subanalysis of GetGoal-S
por: Onishi, Yukiko, et al.
Publicado: (2015)

Circadian rhythms and diabetes
por: Kurose, Takeshi, et al.
Publicado: (2011)

Dietary recommendations for type 2 diabetes patients: Lessons from recent clinical and basic research in Asia
por: Seino, Yusuke, et al.
Publicado: (2019)

Glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1: Incretin actions beyond the pancreas
por: Seino, Yutaka, et al.
Publicado: (2013)

Eating whole fruit, not drinking fruit juice, may reduce the risk of type 2 diabetes mellitus
por: Seino, Yusuke, et al.
Publicado: (2021)

Exendin-4 — A potential therapeutic for type 2 diabetes-linked cervical cancer?
por: Mishra, Nivida, et al.
Publicado: (2021)

Effects of DPP‐4 inhibitor linagliptin and GLP‐1 receptor agonist liraglutide on physiological response to hypoglycaemia in Japanese subjects with type 2 diabetes: A randomized, open‐label, 2‐arm parallel comparative, exploratory trial
por: Yabe, Daisuke, et al.
Publicado: (2016)

A proteomic approach to obesity and type 2 diabetes
por: López-Villar, Elena, et al.
Publicado: (2015)

Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes
por: Seino, Yutaka, et al.
Publicado: (2017)

Predicting efficacy of dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes: Association of glycated hemoglobin reduction with serum eicosapentaenoic acid and docosahexaenoic acid levels
por: Iwasaki, Masahiro, et al.
Publicado: (2012)

Efficacy and safety of oral semaglutide by baseline age in Japanese patients with type 2 diabetes: A subgroup analysis of the PIONEER 9 and 10 Japan trials
por: Yamada, Yuichiro, et al.
Publicado: (2021)

The journey to understanding incretin systems: Theory, practice and more theory
por: Yabe, Daisuke, et al.
Publicado: (2019)

GIP and GLP‐1, the two incretin hormones: Similarities and differences
por: Seino, Yutaka, et al.
Publicado: (2010)

Meal sequence and glucose excursion, gastric emptying and incretin secretion in type 2 diabetes: a randomised, controlled crossover, exploratory trial
por: Kuwata, Hitoshi, et al.
Publicado: (2015)

Sodium‐glucose cotransporter‐2 inhibitor luseogliflozin added to glucagon‐like peptide 1 receptor agonist liraglutide improves glycemic control with bodyweight and fat mass reductions in Japanese patients with type 2 diabetes: A 52‐week, open‐label, single‐arm study
por: Seino, Yutaka, et al.
Publicado: (2017)

Efficacy and safety of sitagliptin as compared with glimepiride in Japanese patients with type 2 diabetes mellitus aged ≥ 60 years (START‐J trial)
por: Terauchi, Yasuo, et al.
Publicado: (2017)

Change in pharmacodynamic variables following once‐weekly tirzepatide treatment versus dulaglutide in Japanese patients with type 2 diabetes (SURPASS J‐mono substudy)
por: Yabe, Daisuke, et al.
Publicado: (2022)

Posttraumatic Stress Disorder and Incident Type 2 Diabetes: Is Obesity to Blame?
por: Scherrer, Jeffrey F., et al.
Publicado: (2019)

Mouse models and the interpretation of human GWAS in type 2 diabetes and obesity
por: Cox, Roger D., et al.
Publicado: (2011)

Real-world Observational Study on Patient Outcomes in Diabetes (RESPOND): study design and baseline characteristics of patients with type 2 diabetes newly initiating oral antidiabetic drug monotherapy in Japan
por: Yabe, Daisuke, et al.
Publicado: (2020)

Role of a Dual Glucose-Dependent Insulinotropic Peptide (GIP)/Glucagon-like Peptide-1 Receptor Agonist (Twincretin) in Glycemic Control: From Pathophysiology to Treatment
por: Pelle, Maria Chiara, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_smdlrfr45agv20o7auiuq9mtl9